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Overlooked in Fallon?
The statistical examination of the Fallon
childhood cancer cluster by Steinmaus et al.
(2004) provides renewed justification for
opening a larger window onto the expanse
of possibilities regarding a possible cause for
this extraordinary cluster. Although the
cause(s) might very well be the culmination
of simultaneous or sequential exposure to an
array of chemical stressors (perhaps in con-
junction with nonchemical stressors) at the
needed concentrations for sufficient time
and during critical windows of vulnerability
(as dictated by health and nutritional status,
age, sex, genetic susceptibility, etc.), it is
worth considering possible new, plausible
singular causes until each is ruled out. 
Significant resources have been devoted
to investigating the childhood cancer cluster
discovered in 2000 in Fallon, Nevada
(Churchill County). Although the magni-
tude of this cluster of acute lymphoblastic
leukemia (ALL) could be attributed to
happenstance, the recent analysis by
Steinmaus et al. (2004) shows that such a
cluster would be expected to occur in the
United States by chance less frequently than
every 20,000 years. 
A surprising, contemporaneous incidence
of ALL also developed in Sierra Vista,
Arizona (Cochise County Health Department
2004). Other clusters have occurred in seve-
ral additional western U.S. rural communi-
ties, as well as in various locales worldwide.
Of possible significance has been the simul-
taneous emergence in both Churchill and
Cochise counties of an extremely rare form
of childhood cancer, rhabdomyosarcoma. 
None of the hypothesized causes of the
Fallon cluster has withstood scrutiny (with
the possible exception of an unknown
infectious agent—the “population mixing”
hypothesis or “Kinlen theory,” although not
supported by the examination of Steinmaus
et al. 2004), including exposure to arsenic,
tungsten, radiation, and jet fuel. Any
hypothesis must account for the important
fact that these clusters seem to be limited to
a span of several years, after which the inci-
dence subsides. Another commonality seems
to be arid agricultural locales that experience
periods of drought. 
Surprisingly, despite the extensive
resources and time devoted to searching for
an environmental etiology, no considera-
tion has been devoted to one potential
cause that would account for many, if not
all, of the aspects of these clusters.
Pyrrolizidine alkaloids (PAs) comprise a
complex galaxy of highly bioactive natural
products. Riddelliine, senkirkine, mono-
crotaline, retronecine, heliotridine, jacoline,
jacozine, jacobine, seneciphylline, and
senecionine are but a few of the numerous
PAs produced by a wide spectrum of plants.
PA-producing plants (e.g., tansy ragwort,
coltsfoot, hound’s tongue), especially Senecio
species, have long been problematic in the
western United States and are well known
for livestock poisonings. 
Fluctuating levels of PA contamination
in the consumer food supply, especially via
certain herbal teas (e.g., comfrey), honey
(Beales et al. 2004), dairy products, beef,
and grains, are a function of drought and
harvest or foraging conditions, and therefore
exhibit aperiodic cycles of high expression.
Churchill County happens to be the center
of honey production in Nevada (Churchill
Co. 2005; Michigan State University
Extension 2002); honey is also produced in
Cochise County. Honey has been a particu-
lar focus for PA contamination; levels can
vary from hive to hive by two or more
orders of magnitude within the same forag-
ing location and by time of year. PA-pro-
ducing plants are particularly prevalent in
both counties, where they can contaminate
the domestic food supply as weeds; some,
such as comfrey, continue to be sold by cer-
tain vendors of nutritional supplements and
health foods. 
Sporadic acute exposures or long-term
exposure to low levels (e.g., as little as
10 µg/day) of PAs can lead to delayed toxic-
ity (Australia New Zealand Food Authority
2001; Molyneux et al. 1988) (up to 1 or
more years after exposure) and could there-
fore escape causal suspicion or elude
measurement. Levels of metabolites insuffi-
cient for overt toxicity in adults could be
passed from mothers to fetuses and nursing
infants. Maternal transfer would also exempt
the liver as the major target for the well-doc-
umented toxicity for these chemicals.
Furthermore, ALL can originate in utero
(Jensen et al. 2004). Although best known
for their hepatotoxicity (where the bioactive
metabolites, such as the dehydropyrrolic
products, lead to veno-occlusive diseases and
cirrhosis), activated PAs can elicit significant
genotoxicity and can be carcinogenic as well
as anticarcinogenic (which has led to their
experimental use in chemotherapy). Some
PA adducts persist in tissues from which
metabolites can be released, even long after
initial exposure, and migrate to other tissues
or can be transported to fetuses or nursing
infants (Molyneux and James 1990). It is
noteworthy that honey, milk, and grains are
also common foods for infants. 
Although carcinogenicity data are
lacking in humans, PAs have been shown
in rats to cause both leukemia (Chan et al.
2003) and rhabdomyosarcoma [California
Environmental Protection Agency (EPA)
1999]. The Food and Drug Administration
(FDA 2001), the National Toxicology
Program (NTP 2003), the World Health
Organization (WHO 1988), the California
EPA (1999), and others have identified
PAs as a major human health threat, espe-
cially for fetuses and infants. Significantly,
a recent study (Jensen et al. 2004) points
for the first time to a link between mater-
nal diet and ALL, where consumption of
carotenoids and glutathione (via vegetables)
is proposed as being protective. Although
linkages of cancer with diet often ascribe
the cause to deficiencies or insufficiencies
of essential or protective nutrients, just as
likely would be the presence of particular
chemical stressors—anthropogenic and
natural toxicants alike. This finding of
Jensen et al. (2004) fits nicely with the fact
that glutathione conjugation in particular
is known to be a major detoxification route
for PAs. A coordinated investigation by
epidemiologists, toxicologists, and environ-
mental chemists of a PA–leukemia linkage
could prove to be a prudent investment. 
The author declares he has no competing
financial interests.
Christian G. Daughton
Henderson, Nevada 
E-mail: daughton@gmail.com
REFERENCES
Australia New Zealand Food Authority. 2001. Pyrrolizidine
Alkaloids in Food: A Toxicological Review and Risk
Assessment. Technical Report Series No. 2. Canberra,
Australia:Australia New Zealand Food Authority.
Available: http://www.foodstandards.gov.au/_srcfiles/
TR2.pdf [accessed 2 March 2005].
Beales KA, Betteridge K, Colegate SM, Edgar JA. 2004. Solid-
phase extraction and LC-MS analysis of pyrrolizidine
alkaloids in honeys. J Agric Food Chem 52(21):6664–6672.
California EPA. 1999. Safe Drinking Water and Toxic
Enforcement Act of 1986 (Proposition 65). Availability of
Draft Data Summaries and Draft Priorities for Chemicals
With Respect to Their Potential to Cause Cancer: Request
for Relevant Information. Sacramento, CA:California
Environmental Protection Agency, Office of Environmental
Health Hazard Assessment. Available: http://www.oehha.
ca.gov/prop65/pdf/batch3_8.pdf [accessed 1 March 2005].
Chan PC, Haseman JK, Prejean JD, Nyska A. 2003. Toxicity and
carcinogenicity of riddelliine in rats and mice. Toxicol Lett
144(3):295-311.
Churchill Co. 2005. Churchill County, Nevada Homepage.
Available: http://www.usgennet.org/usa/nv/state/
alhn-churchill/alhn-churchill.htm [accessed 2 March 2005].
Cochise County Health Department. 2004. Leukemia Cluster
Information for Cochise County. County of Chochise,
Arizona:Cochise County Health Department. Available:
http://www.co.cochise.az.us/health/HealthDepartment/
Leukemia.htm [accessed 2 March 2005].
FDA. 2001. FDA Advises Dietary Supplement Manufacturers
A 224 VOLUME 113 | NUMBER 4 | April 2005 • Environmental Health Perspectives
Perspectives  Correspondence
The correspondence section is a public forum and, as such, is not peer-reviewed. EHP is not responsible
for the accuracy, currency, or reliability of personal opinion expressed herein; it is the sole responsibility of
the authors. EHP neither endorses nor disputes their published commentary.to Remove Comfrey Products from the Market [letter to
industry]. College Park, MD:Center for Food Safety and
Applied Nutrition, Food and Drug Administration.
Available: http://www.cfsan.fda.gov/~dms/dspltr06.html
[accessed 1 March 2005].
Jensen CD, Block G, Buffler P, Ma X, Selvin S, Month S. 2004.
Maternal dietary risk factors in childhood acute lympho-
blastic leukemia (United States). Cancer Causes Control
15(6):559–570.
Michigan State University Extension. 2002. Agricultural
Tourism in Cochise County, Arizona Characteristics and
Economic Impacts. Tourism Educational Materials -
33839801. Available: http://www.msue.msu.edu/msue/
imp/modtd/33839801.html [accessed 2 March 2005].
Molyneux RJ, James LF. 1990. Pyrrolizidine alkaloids in
milk: thresholds of intoxication. Vet Hum Toxicol
32(suppl):94–103.
Molyneux RJ, Johnson AE, Stuart LD. 1988. Delayed manifes-
tation of Senecio-induced pyrrolizidine alkaloidosis in
cattle: case reports. Vet Hum Toxicol 30(3):201–205.
NTP. 2003. Toxicology and Carcinogenesis Studies of
Riddelliine (CAS No.23246-96-0) in F344/N Rats and B6C3F1
Mice (Gavage Studies). Technical Report 508. Research
Triangle Park, NC:National Toxicology Program.
Steinmaus C, Lu M, Todd RL, Smith AH. 2004. Probability esti-
mates for the unique childhood leukemia cluster in Fallon,
Nevada, and risks near other U.S. military aviation facili-
ties. Environ Health Perspect 112:766–771.
WHO. 1988. Pyrrolizidine Alkaloids. Environmental Health
Criteria No. 80. Geneva:World Health Organization.
Available: http://www.inchem.org/documents/ehc/
ehc/ehc080.htm [accessed 1 March 2005].
Editor’s note: In accordance with journal
policy, Steinmaus et al. were asked whether
they wanted to respond to this letter, but they
chose not to do so.
“Arsenic in Food”: Opinion
Parading as Science
I write in response to apparent serious errors
associated with Ellen K. Silbergeld’s letter in
the May 2004 issue of EHP (Silbergeld
2004). As a toxicologist of nearly 30 years, a
private consultant, and associate editor of the
International Journal of Toxicology, I am con-
cerned that although Silbergeld’s assertions
on the risk of arsenic residues in poultry are
presented under the cloak of good science,
they appear to be her personal opinions and
not a scientific conclusion based on sound
methodology and evidence. In her letter I
found at least three significant deviations
from sound scientific methodology. These
included the multiple mischaracterization of
results presented in other publications and
the introduction of a serious mathematical
error. I will discuss in detail only one of
these, the mathematical error, which should
suffice to demonstrate the lack of science
supporting Silbergeld’s opinion letter.
In one of the articles Silbergeld relied
upon, “Mean Total Arsenic Concentrations
in Chicken 1989–2000 and Estimated
Exposures for Consumers of Chicken” by
Lasky et al. (2004), the authors estimated
that, based on the consumption of 60 g/day
of chicken meat, an average individual may
ingest 1.38–5.24 µg/day inorganic arsenic.
However, in employing these numbers in
her letter, Silbergeld stated the units erro-
neously and reported the results of Laskey
et al. as 1.38–5.24 µg/kg/day inorganic
arsenic. This single error inflated the alleged
“exposure” rate by 7,000%, a significant
miscalculation. In fact, this error, by itself,
completely negates Silbergeld’s opinion that
inorganic arsenic exposure through the con-
sumption of chicken “would be a significant
addition to drinking water exposure.” 
This misquoting of Lasky et al.’s (2004)
results is but one of Silbergeld’s significant
mistakes in her letter. The result of each
error of this type is either an inflation of the
calculated exposure or a buttressing of
Silbergeld’s stated opinion. 
As a long-time author, reviewer, and edi-
tor of scientific papers, I am aware of the dif-
ficulty in ensuring the detailed accuracy of
manuscripts, particularly where letters are
concerned. There is a historical, although
incorrect, perception that letters deserve less
review than full manuscripts. At the same
time some individuals, knowing that letters
are not peer-reviewed to the same degree as
scientific articles, make use of letters to get
into print content that would otherwise not
be acceptable. Although this may not have
been the objective of Silbergeld’s letter, her
scientifically unsupported opinion was
repeated in the Baltimore Sun (O’Brien 2004)
and other media (e.g., Consumer Reports
2005) as though it were scientifically proven
fact. The result was unnecessary public alarm
based on unsupported personal opinions.
Peer-review is meant to identify and weed
out mistakes of this type. Ethical journals
either require authors to correct errors before
publication or decline to publish the article if
the author refuses to make the warranted
changes. Peer-review is not only the job of
the publishing journal, but also the institu-
tion where the author resides (in this case,
Johns Hopkins University). At many institu-
tions, anything intended for publication must
withstand internal review by an institutional
committee before it can be sent to a potential
publisher. For some reason, neither institu-
tional nor editorial review detected these mis-
quoted results and mathematical errors, a
number of which appear to be obvious and
would have been easily detected had the letter
been checked. Both the journal and institu-
tion may wish to review their current proce-
dures and make adjustments so they are not
similarly embarrassed in the future.
As professionals, health scientists must
be cognizant that respectability and trust
are fragile commodities. We all know too
well of a number of professions in our soci-
ety that have lost significant amounts of
respect and trust (e.g., politicians, lawyers,
clergy) because of the misuse of the trust
placed in them. Rational thought, balanced
and unbiased evaluation, and honest report-
ing, as exemplified by the scientific method,
are the primary underpinnings of the trust
with which the nonscientific community
honors us. Anything that causes loss of that
trust, whether sloppy work or biased, self-
serving presentations that distort the true
state of scientific knowledge, demeans us all. 
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Editor’s note: Lasky et al. were given the
opportunity to respond to Silbergeld’s letter
[Environ Health Perspect 112:A338–A339
(2004)], but they declined; we omitted that
fact when we published Silbergeld’s letter. 
“Arsenic in Food”: Silbergeld
Responds
Bernard comments on the calculations in my
letter (Silbergeld 2004) to criticize my con-
clusions, which were that the use of arsenic
for growth promotion in poultry feeds results
in contamination of chicken products (and
other food animal products because of the
use of poultry litter in feeds), and that the
estimates of risk have not been adequately
calculated, even by Lasky et al. (2004)
because of unsubstantiated inferences of the
arsenic concentrations in edible tissues and a
puzzling use of outdated risk assessments for
arsenic. I find it interesting that Bernard
(who has consulted for the Food and Drug
Administration, the agency that permits this
nontherapeutic use of arsenicals in animal
feeds) does not comment on these conclu-
sions in his letter.
I acknowledge the error in quoting Lasky
et al. (2004); I used the wrong metric in
quoting her conclusions. Please do not
ascribe responsibility to my colleagues, who
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EHP’s editorial office. However, I do not
agree that this mistake invalidates the conclu-
sions of my letter. If the concentrations of
arsenic in edible chicken meat are not one-
tenth of those in liver (as claimed by
Alpharma, the manufacturer of roxarsone),
then the exposure of Americans who con-
sume chicken (such as my son, who appeared
to exist largely on chicken wings during high
school) is in fact 3–10 times higher than
Lasky et al. estimated, resulting in an intake
of 4–50 µg/day. This is still in excess of the
current National Research Council (NRC)
recommendation (NRC 2001).
This risk estimate does not include the
potential for additional exposures to arsenic
from confined animal feeding operation
(CAFO) wastes via land disposal, which may
reach human populations though soil con-
tact, groundwater contamination, and plant
uptake, as noted in my letter (Silbergeld
2004). These exposures may be important
for regions such as the Eastern Shore, where
between 600 and 800 million broiler chick-
ens are raised each year. The U.S. Geological
Survey has estimated that thousands of kilo-
grams of arsenic may be land disposed with
poultry wastes (Garbarino et al. 2003).
Given the article by Lasky et al. (2004)
and new information on the environmental
pathways of arsenic releases from CAFOs
(Han et al. 2004; Jackson et al. 2003), as
well as new studies on the health effects of
arsenicals (Simeonova and Luster 2004), I
suggest that it is time for a thoughtful con-
sideration of the use of arsenicals as growth
promoters in animal feeds. 
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“Sex and Ceruloplasmin
Modulate the Response to
Copper ...” 
It is past time for EHP to stop accepting
papers whose funding disclosure makes it
obvious there is a conflict, yet “The authors
declare they have no competing financial
interests.” Méndez et al. (2004) stated that
“This investigation was funded by the
International Copper Association [ICA] in
the form of an unrestricted research grant.” I
fail to see that an unrestricted grant elimi-
nates a conflict of interest. From the article’s
introduction, it is obvious that this research
team has done a lot of copper toxicity work
with this money from the ICA, but the con-
flict of interest would exist even if only the
work reported in this article was funded by
the ICA.
It is interesting, however, that the ICA
is funding human experimentation. The
pesticide industry’s push to allow human
experimentation in the toxicity tests to reg-
ister their pesticides in the United States is
driven by their resulting ability to drop the
10-fold interspecies safety factor in allow-
able exposure levels. Lockwood (2004)
found all six human pesticide studies
reviewed rife with financial conflict of inter-
ests. Think of the risks created to all toxicity
testing when the most reputable general
toxicology journal in the world, EHP,
endorses human subjects for toxicity testing
in very risky situations.
Many of us tolerate animal testing
because we hope that eventually the current
massive risk of toxic agents will be acknowl-
edged. 
It may seem that this work on Cu
entailed little risk, as the authors claim in
the opening of their discussion: 
… Liver aminotranferases were evaluated to satisfy
ethical considerations. We detected no responses
that may represent toxic effects of the Cu dose
used.
First, the authors acknowledged that
there are large data gaps on the toxicity of
Cu at many doses. Critically, this demonstra-
ble truth makes their statement about detect-
ing no toxic responses false. Obviously they
were not looking at many toxic end points—
especially chronic effects. Also, they stopped
looking for any effects after a very short
period (82 subjects ingested 10 mg/kg/day
Cu for 2 months).
The stated tolerable daily intake (TDI)
in the introduction (Méndez et al. 2004) is
unclear (and unattributed), but it appears to
range from 0.9 to 10 mg/kg/day. The
experimental dose chosen for this study was
10 mg/kg/day, and was justified by the
authors as being a dose safe for 97.5% of
humans. TDIs are typically derived from
industry junk science (unpublishable in
independent journals) and contain massive
data gaps. However, even if we assume the
claimed TDI is validated, the authors are
admiting that their chosen experimental
dose was above the “safe” level for about
two of their subjects.
At the end of the discussion the authors
admit that the Cu-induced enzyme changes
they looked at are altered by hepatic dis-
eases; Méndez et al. (2004) then state that
their results can be used to monitor adverse
liver effects.
The effect of the combination of risky
dosing with acknowledged toxicity data gaps
is stunning. In summary, I am disappointed
that EHP’s manuscript reviewers and editors
allowed such dangerous (unethical) statements
and objective inconsistencies; I fear that a
human toxicity experiment—in EHP of all
places—has created a terrible precedent; and I
am frustrated that authors and EHP continue
to misstate obvious conflicts of interest. I look
forward to discussion and solutions.
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Ceruloplasmin and Copper:
Méndez and Araya Respond
Most unfortunately, Tweedale misunder-
stood and misinterpreted our article “‘Sex and
Ceruloplasmin Modulate the Response to
Copper Exposure in Healthy Individuals”
(Mendéz et al. 2004). The article is about
copper homeostasis and homeostatic regula-
tion, not about toxic effects associated with
copper. The dose administered was
10 mg/day and not 10 mg/kg/day, which we
agree may be toxic. The dosage and the time
of study used allowed us to assess homeostatic
mechanisms in normal human beings; this
study will contribute to the development of
specific recommendations for subgroups of
the population that have genetic polymor-
phisms that render them more susceptible to
minor copper deficiency and copper excess. 
Aminotranferases are the current gold
standard to assess liver damage; therefore, it is
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expected because the dose is safe, ethical con-
siderations made it pertinent to measure their
activities. These enzymatic activities are rou-
tinely measured for diagnostic purposes in
individuals who manifest symptoms of ill-
nesses. It is not known whether they reflect
minor changes in hepatic function when
enzymatic values are within the normal limits
and there is no illness. Thus, it was most
interesting to assess the potential of these
enzymes to detect changes within the normal
range in the studied individuals. 
Certainly, our work is based on a series of
concepts that include the upper safe limit
(which represents the safe chronic average
intake of the metal for human beings), tolera-
ble daily intake (TDI), and several others [e.g.,
dietary allowances, adequate recommended
oral intake (AROI), lower concentration of
observed effects (LOEL)] that served to ensure
that the protocol was within safe limits for
human adults. Although approximately
2–2.5% of the normal population is not
included in some of the concepts mentioned,
this does not mean that this percentage will
be damaged by the exposure but that they
represent individuals with illnesses, and there-
fore are not included among the normal pop-
ulation, who require a different treatment. All
these concepts, of course, are not “typically
derived from industry junk science (unpub-
lishable in independent journals)” and they
do not “contain massive data gaps,” as stated
by Tweedale, but they do represent the state
of the art on a specific topic produced by
experts appointed by the National Institutes
of Health, the World Health Organization,
and other respected agencies.
Our study (Mendéz et al. 2004) indeed
followed the ethical considerations required
to work with human subjects. The protocol
was approved by our institutional review
board, which is registered (IRB00001493)
with the Office for Human Research
Protections.
Last and most important, how to deal
with potential conflicts of interest in science
is a hot topic, and there is currently no final
solution (Blumenthal 2003; Morin et al.
2002; Nathan and Wilson 2003; Tufts
University 2003). We made full disclosure of
our financial support, and it is up to the read-
ers to judge the situation for themselves.
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ERRATA
Lai et al. would like to clarify their financial support for their article “Understanding the
Spatial Clustering of Severe Acute Respiratory Syndrome (SARS) in Hong Kong”
stated that “The research was supported by the Research Fund for the Control of
Government.”
The January Beyond the Bench article “Building Blocks of Learning” [Environ Health
Perspect 113:A33 (2005)] incorrectly listed Kathleen Vandiver's affiliation as Cambridge
Public Schools. Vandiver is actually with Lexington Public Schools. 
The March Science Selections article “Fewer Frogs in Illinois: Organochlorines May Be to
Blame” [Environ Health Perspect 113:A182 (2005)] listed incorrect percentages of intersex
frogs collected during the periods studied. In fact, intersex frogs accounted for 1.2% of
samples from 1852 to 1929, 7.5% of samples from 1930 to 1945, 11.1% of samples from
1946 to 1959, 6.3% of samples from 1960 to 1979, and 2.7% of samples from 1980 to
2001. 
EHP regrets the errors.
Infectious Diseases of the Health, Welfare and Food Bureau of the Hong Kong SAR
[accessed 1 March 2005].
http://techtransfer.tufts.edu/tufts/pol_guide/conflict.html
[Environ Health Perspect 112:1550–1556 (2004)]. The acknowledgment should have